Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwNHL 2017 | Overcoming toxicities when combining PI3K inhibitors with other treatments

Idelalisib was the first phosphoinositide 3-kinase (PI3K) inhibitor to be used in lymphoma, which had remarkable responses on B-cell lymphomas as a single-agent. Nathan Fowler, MD at the University of Texas MD Anderson Cancer Center, Houston, TX talks about the different combination studies with idelalisib, and how we are trying to overcome toxicities found, by developing second-generation PI3K inhibitors, such as copanlisib, umbralisib, and duvelisib.
Recorded at the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2017 annual meeting, held in Vancouver, BC, Canada.